Euronext
Truffle Capital floats Carmat
Artificial heart developer Carmat has launched an IPO on the Alternext of NYSE-Euronext Paris, looking for тЌ15m.
Biotech IPOs under investor microscope
The recent flurry of biotechs seeking to raise capital on the public markets could prove mistimed as question marks are raised over investor appetite. FranУЇois Rowell investigates.